株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨粗鬆症:パイプライン製品の分析

Osteoporosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232788
出版日 ページ情報 英文 247 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
骨粗鬆症:パイプライン製品の分析 Osteoporosis - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 247 Pages
概要

骨粗鬆症は、骨量の減少により骨の強度が弱まり骨折しやすくなる疾患です。加齢、性別、低体重、性ホルモンの不足または閉経、喫煙、ある種の薬剤による発症のリスクがあります。症状は脊椎の破損や圧迫骨折による腰痛、身長の低下、前屈姿勢、容易な骨折などであり、予防または治療として、カルシウム、ビタミンDの摂取、運動、治療薬による治療が挙げられます。

当レポートでは、骨粗鬆症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

骨粗鬆症 - 概要

骨粗鬆症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

骨粗鬆症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

骨粗鬆症の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Alize Pharma SAS
  • Alvogen Korea Co Ltd
  • Amgen Inc
  • Amura Holdings Ltd
  • BiologicsMD Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Company
  • Cellmid Ltd
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corium International Inc
  • Critical Pharmaceuticals Ltd
  • 第一三共
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzo Biochem Inc
  • F. Hoffmann-La Roche Ltd
  • Gador SA
  • GL Pharm Tech Corp
  • Glide Pharmaceutical Technologies Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Haoma Medica Ltd
  • Immunovo BV
  • Immunwork Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Kaken Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Ligand Pharmaceuticals Inc
  • Lotus Pharmaceutical Co Ltd
  • Lupin Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • NIBEC
  • Omeros Corp
  • Oncobiologics Inc
  • Osteologix Holdings Plc
  • Paras Biopharmaceuticals Finland Oy
  • Pfenex Inc
  • PhytoHealth Corp
  • R Pharm
  • Ribomic Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinil Pharmaceutical Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Terpenoid Therapeutics Inc
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Viking Therapeutics Inc
  • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Yooyoung Pharm Co Ltd
  • Zydus Cadila Healthcare Ltd

薬剤プロファイル

骨粗鬆症 - 休止中のプロジェクト

骨粗鬆症 - 開発が中止された製品

骨粗鬆症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9263IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 5, 5, 11, 57, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteoporosis - Overview
    • Osteoporosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Osteoporosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Osteoporosis - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Alize Pharma SAS
    • Alvogen Korea Co Ltd
    • Amgen Inc
    • Amura Holdings Ltd
    • BiologicsMD Inc
    • Bone Biologics Corp
    • Bristol-Myers Squibb Company
    • Cellmid Ltd
    • ChoDang Pharm Co Ltd
    • Chugai Pharmaceutical Co Ltd
    • Corium International Inc
    • Critical Pharmaceuticals Ltd
    • Daiichi Sankyo Company Ltd
    • ElexoPharm GmbH
    • EndoCeutics Inc
    • Entera Bio Ltd
    • Enteris BioPharma Inc
    • Enzo Biochem Inc
    • F. Hoffmann-La Roche Ltd
    • Gador SA
    • GL Pharm Tech Corp
    • Glide Pharmaceutical Technologies Ltd
    • Hanmi Pharmaceuticals Co Ltd
    • Haoma Medica Ltd
    • Immunovo BV
    • Immunwork Inc
    • Intas Pharmaceuticals Ltd
    • Ipsen SA
    • Kaken Pharmaceutical Co Ltd
    • Lead Discovery Center GmbH
    • Ligand Pharmaceuticals Inc
    • Lotus Pharmaceutical Co Ltd
    • Lupin Ltd
    • Merck & Co Inc
    • Mereo Biopharma Group Plc
    • NIBEC
    • Omeros Corp
    • Oncobiologics Inc
    • Osteologix Holdings Plc
    • Paras Biopharmaceuticals Finland Oy
    • Pfenex Inc
    • PhytoHealth Corp
    • R Pharm
    • Ribomic Inc
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    • Shin Poong PharmCo Ltd
    • Sinil Pharmaceutical Co Ltd
    • Stelis Biopharma Pvt Ltd
    • Sumitomo Dainippon Pharma Co Ltd
    • Terpenoid Therapeutics Inc
    • TSH Biopharm Corporation Ltd
    • Uni-Bio Science Group Ltd
    • Viking Therapeutics Inc
    • Wroclawskie Centrum Badan EIT+ Sp z oo
    • Yooyoung Pharm Co Ltd
    • Zydus Cadila Healthcare Ltd
  • Osteoporosis - Drug Profiles
    • (acolbifene hydrochloride + prasterone) - Drug Profile
    • (cholecalciferol + raloxifene) - Drug Profile
    • (cholecalciferol + risedronate sodium) - Drug Profile
    • 2-AMD - Drug Profile
    • 3D-QM - Drug Profile
    • 3D-QMS - Drug Profile
    • abaloparatide - Drug Profile
    • ADX-68693 - Drug Profile
    • AKR-215 - Drug Profile
    • AKR-308 - Drug Profile
    • alendronate sodium - Drug Profile
    • AM-3701 - Drug Profile
    • ARC-205 - Drug Profile
    • BCD-700 - Drug Profile
    • BMD-1111 - Drug Profile
    • BMS-777607 - Drug Profile
    • BPS-804 - Drug Profile
    • calcitonin DR - Drug Profile
    • CD-030 - Drug Profile
    • CDR-914K058 - Drug Profile
    • CDRI-99/373 - Drug Profile
    • CH-5036249 - Drug Profile
    • denosumab - Drug Profile
    • denosumab biosimilar - Drug Profile
    • denosumab biosimilar - Drug Profile
    • denosumab biosimilar - Drug Profile
    • denosumab biosimilar - Drug Profile
    • Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile
    • Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
    • DS-1501 - Drug Profile
    • eldecalcitol - Drug Profile
    • Eu-232 - Drug Profile
    • Ewha-18278 - Drug Profile
    • genipin - Drug Profile
    • HCP-1405 - Drug Profile
    • HCP-1604 - Drug Profile
    • IG-8801 - Drug Profile
    • IHBD-1 - Drug Profile
    • IPS-02001 - Drug Profile
    • KAL-671 - Drug Profile
    • KKM-0805 - Drug Profile
    • KKM-0902 - Drug Profile
    • KN-012 - Drug Profile
    • lasofoxifene tartrate - Drug Profile
    • MAb-4 - Drug Profile
    • MDY-1001 - Drug Profile
    • Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
    • Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis - Drug Profile
    • NBS-101 - Drug Profile
    • NEP-28 - Drug Profile
    • OGX-528 - Drug Profile
    • OXY-133 - Drug Profile
    • OXY-149 - Drug Profile
    • OXY-153 - Drug Profile
    • PF-708 - Drug Profile
    • PHN-031 - Drug Profile
    • Protein to Antagonize PPAR Gamma-2 for Rheumatoid Arthritis, Obesity and Osteoporosis - Drug Profile
    • Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile
    • R-Spondin 1 - Drug Profile
    • RBM-007 - Drug Profile
    • Recombinant Peptide to Agonize PTH1R for Osteoporosis - Drug Profile
    • Recombinant Protein 1 for Osteoporosis and Rheumatoid Arthritis - Drug Profile
    • Recombinant Protein 2 for Osteoporosis and Rheumatoid Arthritis - Drug Profile
    • Recombinant Protein 3 for Osteoporosis and Rheumatoid Arthritis - Drug Profile
    • Recombinant Protein for Bone Disorders and Osteoporosis - Drug Profile
    • Recombinant Protein for Osteoporosis and Osteoarthritis - Drug Profile
    • Recombinant Protein for Osteoporosis and Rheumatoid Arthritis - Drug Profile
    • Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile
    • Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
    • romosozumab - Drug Profile
    • RPH-203 - Drug Profile
    • S-0071500 - Drug Profile
    • S-008399 - Drug Profile
    • S-101479 - Drug Profile
    • SI-000513 - Drug Profile
    • Small Molecule for Oncology, Psoriasis and Osteoporosis - Drug Profile
    • Small Molecule for Osteoporosis - Drug Profile
    • Small Molecule to Activate sGC for Osteoporosis - Drug Profile
    • Small Molecule to Agonize Androgen Receptor for Osteoporosis - Drug Profile
    • Small Molecule to Agonize EP4 Receptor for Osteoporosis - Drug Profile
    • Small Molecule to Agonize LRP for Osteoporosis - Drug Profile
    • Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile
    • Small Molecule to Antagonize OGR1 for Asthma, Bone Diseases, Oncology and Osteoporosis - Drug Profile
    • Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis - Drug Profile
    • Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis - Drug Profile
    • Small Molecule to Target LGR4 for Oncology and Osteoporosis - Drug Profile
    • Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis - Drug Profile
    • Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
    • Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
    • Small Molecules for Osteopenia and Osteoporosis - Drug Profile
    • Small Molecules for Osteoporosis - Drug Profile
    • Small Molecules for Osteoporosis - Drug Profile
    • Small Molecules to Antagonize Calcium-Sensing Receptor for Osteoporosis - Drug Profile
    • Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile
    • Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile
    • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    • Small Molecules to Inhibit Sclerostin for Osteoporosis - Drug Profile
    • Small Molecules to Target Estrogen Receptor for Breast Cancer and Osteoporosis - Drug Profile
    • Sodium Quinate - Drug Profile
    • SP-35454 - Drug Profile
    • SR-10171 - Drug Profile
    • SR-2595 - Drug Profile
    • Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
    • Synthetic Peptide for Osteoporosis - Drug Profile
    • Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
    • Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile
    • TE-3110 - Drug Profile
    • TE-3236 - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • UCB-1 - Drug Profile
    • Vaccine to Target Sclerostin for Osteoporosis - Drug Profile
    • VK-5211 - Drug Profile
    • VS-105 - Drug Profile
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Osteoporosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Osteoporosis - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Osteoporosis - Pipeline by Alize Pharma SAS, H1 2017
  • Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Amgen Inc, H1 2017
  • Osteoporosis - Pipeline by Amura Holdings Ltd, H1 2017
  • Osteoporosis - Pipeline by BiologicsMD Inc, H1 2017
  • Osteoporosis - Pipeline by Bone Biologics Corp, H1 2017
  • Osteoporosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Osteoporosis - Pipeline by Cellmid Ltd, H1 2017
  • Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Corium International Inc, H1 2017
  • Osteoporosis - Pipeline by Critical Pharmaceuticals Ltd, H1 2017
  • Osteoporosis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2017
  • Osteoporosis - Pipeline by EndoCeutics Inc, H1 2017
  • Osteoporosis - Pipeline by Entera Bio Ltd, H1 2017
  • Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2017
  • Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2017
  • Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Osteoporosis - Pipeline by Gador SA, H1 2017
  • Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2017
  • Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
  • Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2017
  • Osteoporosis - Pipeline by Immunovo BV, H1 2017
  • Osteoporosis - Pipeline by Immunwork Inc, H1 2017
  • Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
  • Osteoporosis - Pipeline by Ipsen SA, H1 2017
  • Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Osteoporosis - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
  • Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Lupin Ltd, H1 2017
  • Osteoporosis - Pipeline by Merck & Co Inc, H1 2017
  • Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H1 2017
  • Osteoporosis - Pipeline by NIBEC, H1 2017
  • Osteoporosis - Pipeline by Omeros Corp, H1 2017
  • Osteoporosis - Pipeline by Oncobiologics Inc, H1 2017
  • Osteoporosis - Pipeline by Osteologix Holdings Plc, H1 2017
  • Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
  • Osteoporosis - Pipeline by Pfenex Inc, H1 2017
  • Osteoporosis - Pipeline by PhytoHealth Corp, H1 2017
  • Osteoporosis - Pipeline by R Pharm, H1 2017
  • Osteoporosis - Pipeline by Ribomic Inc, H1 2017
  • Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H1 2017
  • Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017
  • Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2017
  • Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2017
  • Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2017
  • Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2017
  • Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2017
  • Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
  • Osteoporosis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Osteoporosis - Dormant Projects, H1 2017
  • Osteoporosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Osteoporosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Osteoporosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Osteoporosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Osteoporosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Osteoporosis - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Osteoporosis - Discontinued Products, H1 2017
  • Osteoporosis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Osteoporosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top